Progesterone Receptor Negative Recruiting Phase 3 Trials for Cefotaxime (DB00493)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02488967Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast CancerTreatment